30th Nov 2015 09:25
LONDON (Alliance News) - Allergy Therapeutics PLC on Monday said it has completed patient enrolment for the PQBirch204 dose selection study for its Pollinex Quattro Birch immunotherapy study.
Allergy said the target sample size of 350 patients for the study has been reached, with the study due to complete by February and the results to be made available in the second quarter of 2016.
"We are excited to be progressing development for another potential product in our ultra-short course, aluminium-free Pollinex Quattro portfolio," said Manual Llobet, Allergy's chief executive.
Allergy shares were up 0.6% to 31.80 pence on Monday.
By Sam Unsted; [email protected]; @SamUAtAlliance
Copyright 2015 Alliance News Limited. All Rights Reserved.
Related Shares:
Allergy Thera.